CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-13 | ROBERTS EIRY Chief Medical Officer | Grant or award · Stock Option 10b5-1 | +22,529 | 22,529 | ||
| 2024-02-13 | ROBERTS EIRY Chief Medical Officer | Grant or award · Restricted Stock Unit 10b5-1 | +4,483 | 4,483 | ||
| 2024-02-13 | Onyia Jude Chief Scientific Officer | Sale 10b5-1 | −1,432 | $132.94 | $190K | 13,128 |
| 2024-02-13 | Onyia Jude Chief Scientific Officer | Grant or award · Stock Option 10b5-1 | +54,069 | 54,069 | ||
| 2024-02-13 | Onyia Jude Chief Scientific Officer | Grant or award · Restricted Stock Unit 10b5-1 | +10,760 | 10,760 | ||
| 2024-02-13 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −1,098 | $132.99 | $146K | 39,740 |
| 2024-02-13 | Lippoldt Darin Chief Legal Officer | Grant or award · Stock Option 10b5-1 | +40,552 | 40,552 | ||
| 2024-02-13 | Lippoldt Darin Chief Legal Officer | Grant or award · Restricted Stock Unit 10b5-1 | +8,070 | 8,070 | ||
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Sale 10b5-1 | −2,832 | $133.02 | $377K | 514,596 |
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Stock Option 10b5-1 | +112,644 | 112,644 | ||
| 2024-02-13 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Restricted Stock Unit 10b5-1 | +22,415 | 22,415 | ||
| 2024-02-13 | Gano Kyle Chief Business Development Off | Sale 10b5-1 | −1,352 | $132.89 | $180K | 135,166 |
| 2024-02-13 | Gano Kyle Chief Business Development Off | Grant or award · Stock Option 10b5-1 | +45,058 | 45,058 | ||
| 2024-02-13 | Gano Kyle Chief Business Development Off | Grant or award · Restricted Stock Unit 10b5-1 | +8,966 | 8,966 | ||
| 2024-02-13 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −716 | $133.03 | $95K | 7,507 |
| 2024-02-13 | Delaet Ingrid Chief Regulatory Officer | Grant or award · Stock Option 10b5-1 | +28,161 | 28,161 | ||
| 2024-02-13 | Delaet Ingrid Chief Regulatory Officer | Grant or award · Restricted Stock Unit 10b5-1 | +5,604 | 5,604 | ||
| 2024-02-13 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −796 | $133.04 | $106K | 17,976 |
| 2024-02-13 | Cooke Julie Chief Human Resources Officer | Grant or award · Stock Option 10b5-1 | +28,161 | 28,161 | ||
| 2024-02-13 | Cooke Julie Chief Human Resources Officer | Grant or award · Restricted Stock Unit 10b5-1 | +5,604 | 5,604 |
Page 37 of 37 · 740 trades